Skip to Content Facebook Feature Image

Ulike Unveils Ulike X, Its First Men's Hair Removal Device in North America

Business

Ulike Unveils Ulike X, Its First Men's Hair Removal Device in North America
Business

Business

Ulike Unveils Ulike X, Its First Men's Hair Removal Device in North America

2024-10-10 00:22 Last Updated At:00:45

NEW YORK, Oct. 10, 2024 /PRNewswire/ -- Ulike, the global leader of at-home IPL (Intense Pulsed Light) laser hair removal, is thrilled to announce the launch of Ulike X, the first professional IPL hair removal product in North America specifically designed for men. This innovative device promises long-lasting results, allowing men to break free from the tedious routine of daily shaving and embrace a lifestyle of freedom, health, and confidence.

Ulike X: Engineered for Men's Hair

For men who are fitness enthusiasts, hair can sometimes obscure the definition of smooth, clear muscle contours. The Ulike X is designed with this concern in mind. Removing body hair can enhance the appearance of muscles and improve athletic performance. Cyclists, for instance, can benefit from hair removal to reduce leg friction during long rides, while swimmers may experience reduced water resistance, contributing to better performance. In addition to improving performance, long-lasting hair removal also helps make the wearing of sports gear more comfortable and facilitates post-workout stretching, injury recovery, and rehabilitation treatments.

The Ulike X, utilizing IPL, alleviates common shaving issues like irritation and rapid regrowth, providing a comfortable alternative to costly laser treatments. IPL technology is a clinically approved hair removal method that uses a light spectrum to target melanin in hair follicles, effectively reducing hair growth. This non-invasive technique is gentle on the skin, making it suitable for various body areas, including the face, chest, abdomen, and back.

With over a decade of research and innovation in IPL hair removal, Ulike's engineers and leading dermatology research groups have consistently developed breakthrough solutions that deliver effective, safe, and convenient technology for healthy, hair-free skin. Professor M.R. Hamblin (Ph.D.) of Harvard Medical School, also Chief Scientific Advisor of Ulike Group, said, "I am to merge the most important findings in photomedicine research with Ulike's robust research and development capabilities to attain industry breakthroughs with advanced beauty products."

Specifically designed for managing coarse and thick hair, the Ulike X utilizes Dual Lights and Multi-Pulse Technology to achieve superior hair reduction results. With three customizable modes, it adapts to different skin types and body areas, enabling up to 94.42% hair reduction in just two weeks. This precision allows men to enjoy smooth skin without the hassle of razors, wax strips, or frequent salon visits.

Equipped with self-developed Ice Cooling Technology, the Ulike X maintains a cool 61.4°F, preventing burns and skin irritation for a more comfortable experience. The SkinSensor technology further enhances safety by detecting skin tones, adjusting power settings, and stopping flashes if an area is too dark for safe application. Additionally, a built-in 1mm UV filter protects the skin from harmful ultraviolet light, ensuring a healthy, hair-free experience without the risk of damage.

Ulike IPL devices are designed to offer professional-grade precision and safety in a compact, easy-to-use format. The Ulike X allows men to achieve smooth, hair-free skin in the comfort and privacy of their own homes, without the need for regular clinic visits. It provides long-lasting results that make everyday grooming more efficient and hassle-free. To learn more about Ulike X, please visit: https://www.ulike.com/products/ulike-x-ipl-hair-removal?utm_source=affiliatepr&utm_medium=affiliate

ABOUT ULIKE
Since 2013, Ulike has harnessed the power of clinical technology to produce luxurious, painless, and cost-effective IPL at-home hair removal devices. With powerful IPL and Sapphire Cooling Technology, the devices deliver visible results and are suitable to use on the full body. The devices are FDA-cleared, clinically tested and dermatologist recommended. Since inception, the brand has grown to be a global leader of IPL at-home beauty devices with over 6 million units sold in 49 countries and regions worldwide. As a beauty-tech brand focused on innovation, Ulike allots thirty percent of its annual profits to research and development. This continuous drive for advancement is what has helped the brand secure over 400 global patents and become an international success.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Ulike Unveils Ulike X, Its First Men's Hair Removal Device in North America

Ulike Unveils Ulike X, Its First Men's Hair Removal Device in North America

ADELAIDE, South Australia, Oct. 9, 2024 /PRNewswire/ -- BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organization (CDMO), announced a new partnership with Centivax, Inc., for a project involving cell line development, cell banking and plasmid DNA manufacture. Centivax is developing Cent-Flu, a universal influenza vaccine, consisting of a proprietary multivalent mixture of 22 unique mRNA transcripts delivered as a lipid nanoparticle (LNP) encapsulated mRNA vaccine. In vivo, the vaccine has been demonstrated to convey protection against current, past, and future influenza strains. BioCina will provide proven expertise in the selection of optimal plasmid manufacturing cell lines, Master Cell Bank (MCB) and plasmid manufacturing, to support Centivax's progression to First-in-Human clinical trials.

 BioCina's Chief Executive Officer, Mark W. Womack stated, "We're privileged to support Centivax's breakthrough approach to sustained flu prevention and we couldn't be more excited to be their partner of choice to initiate cGMP manufacturing, thus advancing the journey to bring such an important vaccine to market. This is a tremendous opportunity for the BioCina Team to leverage our world-class capabilities in cell line development, cell banking, and cGMP plasmid production."

Centivax's Chief Executive Officer, Jacob Glanville, said, "We are thrilled to announce BioCina as our Master Cell Bank manufacturing partner for the first phase of manufacturing our universal influenza vaccine. BioCina's exemplary expertise and track record in mRNA/LNP MCB, combined with their state-of-the-art facilities, aligns perfectly with Centivax's commitment to innovation and quality. This partnership enables us to leverage BioCina's expertise to ensure the highest standards of vaccine production. Together, we're taking a significant step forward in bringing our universal influenza vaccine to market, with the goal of providing broad, lasting protection against the disease on a global scale."

About BioCina
BioCina is a global end-to-end biologics Contract Development and Manufacturing Organisation (CDMO), offering highest-quality, cost-effective cell line, process, analytical and formulation development, and cGMP clinical & commercial manufacturing for the microbial, pDNA and mRNA modalities. BioCina's first facility in Adelaide, South Australia has a rich history of developing and manufacturing both clinical and commercial drug substance, backed by most critical SME's having an average tenure of 15+ years at the site. BioCina boasts an elite quality record having successfully passed regulatory inspections by the US FDA, EMA, TGA and Health Canada. Through a partnership with NovaCina, BioCina offers clients a highest-quality fill-and-finish solution. BioCina is proud to have clients globally, including the U.S., Europe, and the Asia Pacific. Australia offers one of the most attractive tax incentives globally (up to 48.5% cash refund), and one of the world's premier trial networks, making it an ideal destination for biologics companies looking to invest in scaling-up and manufacturing products. Visit https://biocina.com.

About Centivax
Centivax is a universal vaccine platform technology company founded and led by experts in vaccinology, vaccine regulatory affairs, immunology, and computational bioengineering. The universal vaccine platform intellectual property has demonstrated unprecedented breadth of protection against influenza and coronaviruses. The platform delivers ultra-broad neutralizing titers, HAI titers and in-vivo protection in ferrets, pigs, rats, mice and human immune organoids. Development of the Centivax platform has been financially supported by the Global Health Investment Corporation (GHIC) BARDA venture arm, NFX, BLUE KNIGHTâ„¢ J&J/BARDA program, the Bill and Melinda Gates Foundation, the National Institute of Health (NIH), the Naval Medical Research Center, the Walter Reed Army Institute of Research, the Medical Technology Enterprise Consortium, the Department of Defense, and the National Institute for Innovation in Manufacturing Biopharmaceuticals. Centivax is on a mission to accelerate the world's transition to a post-pathogen humanity.

Media Contact
media@biocina.com 

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Centivax Selects Global CDMO BioCina to Initiate cGMP Manufacturing of Revolutionary Universal Influenza Vaccine

Centivax Selects Global CDMO BioCina to Initiate cGMP Manufacturing of Revolutionary Universal Influenza Vaccine

Recommended Articles